Related Experiment Videos
Gastrointestinal stromal tumor (GIST)
Mitchell L Schubert1, Robert Moghimi
1Division of Gastroenterology, 111N, McGuire VAMC, Richmond, VA 23249, USA. mitchell.Schubert@med.va.gov
Current Treatment Options in Gastroenterology
|March 17, 2006
Summary
Gastrointestinal stromal tumors (GISTs) are the most common GI neoplasms, primarily occurring in the stomach. Diagnosis relies on CD117 (KIT protein) staining, with size and mitotic activity predicting malignancy.
Area of Science:
- Gastroenterology
- Oncology
- Pathology
Background:
- Gastrointestinal stromal tumors (GISTs) are the most common nonepithelial neoplasms of the GI tract, frequently found in the stomach.
- Previously misclassified as smooth muscle tumors, GISTs are now recognized as distinct clinicopathologic entities.
- All GISTs possess malignant potential, exhibiting variable aggressiveness.
Purpose of the Study:
- To summarize the clinicopathologic features, diagnosis, and treatment of GISTs.
- To highlight the importance of immunohistochemical markers in GIST diagnosis.
- To discuss the prognostic indicators and therapeutic strategies for GIST management.
Main Methods:
- Review of existing literature on GISTs.
- Analysis of diagnostic criteria, including immunohistochemistry for CD117 (KIT protein).
- Evaluation of prognostic factors such as tumor size and mitotic activity.
Main Results:
- GISTs are characterized by the expression of CD117 (KIT protein).
- Tumor size and mitotic rate are key predictors of malignant behavior.
- Surgical resection is the primary treatment for high-risk GISTs.
Conclusions:
- GISTs require careful evaluation due to their inherent malignant potential.
- Accurate diagnosis through CD117 (KIT protein) immunohistochemistry is crucial.
- Targeted therapies, such as imatinib, have significantly improved outcomes for advanced GIST cases.